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Summary  Over  the  last  decade,  it  has  been  clearly  established  that  one-third  of  all  paragan-
gliomas are  genetically  determined.  Genetic  testing,  guided  by  the  family  history  and  clinical
ﬁndings, must  now  be  proposed  to  all  subjects  undergoing  surgery  for  head  and  neck  paragan-
glioma. When  a  mutation  is  identiﬁed  on  one  of  the  susceptibility  genes  (SDHD,  SDHB,  SDHC,
SDHAF2, VHL),  at-risk  subjects  should  be  investigated  for  the  presence  of  other  supra-  and  infra-
diaphragmatic  paragangliomas  and  functional  catecholamine-secreting  paragangliomas  and/or
phaeochromocytomas.  Identiﬁcation  of  a  germline  mutation  on  the  SDHB  gene  is  a  high-risk  fac-
tor for  malignancy  and  poor  prognosis  and  requires  close  surveillance  of  subjects  carrying  this
mutation. The  diagnosis  of  hereditary  paraganglioma  also  allows  predictive  genetic  screening
in ﬁrst-degree  relatives  of  the  index  subject.  Genetic  testing  for  paraganglioma  is  therefore
now an  important  component  of  the  diagnostic  and  therapeutic  management  of  these  patients.
© 2012  Published  by  Elsevier  Masson  SAS.
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Considerable  progress  has  been  made  in  the  genetics  of  para-
ganglioma  over  the  last  10  years.  Before  2000,  following  the
description  of  various  affected  families  [1],  only  one  genet-
ically  determined  form  of  the  disease  was  thought  to  exist,
but  it  has  now  been  shown  that  about  30%  of  paragangliomas
are  genetically  determined  due  to  the  presence  of  a  con-
stitutional  mutation  on  one  of  the  six  susceptibility  genes
identiﬁed  to  date  (SDHD,  SDHB,  SDHC,  SDHA,  SDHAF2,  VHL).
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doi:10.1016/j.anorl.2012.04.007n  familial  forms,  tumours  occur  earlier,  are  frequently  bilat-
ral  or  even  multifocal,  recurrent  and/or  malignant  and  can
e  associated  with  phaeochromocytoma  [2,3].
Four  chromosomal  regions  with  a  PGL  locus  were  initially
dentiﬁed  by  genetic  linkage  studies  on  large  Dutch,  Amer-
can  and  German  families.  The  PGL1  locus  is  situated  on
hromosomal  band  11q21  [4],  PGL2  on  11q13  [5],  PGL3  on
q21  [6]  and  PGL4  on  1p36  [7].  The  genes  carried  by  these
our  loci  have  been  identiﬁed  over  the  last  decade:  SDHD  for
GL1  [8],  SDHAF2  for  PGL2  [9],  SDHC  for  PGL3  [10], SDHB
or  PGL4  [7].  The  mode  of  transmission  is  autosomal  dom-
nant,  but  subject  to  maternal  genomic  imprinting  for  the
GL1  [11]  and  PGL2  [12]  loci.  SDHA  gene  mutations  were
ecently  identiﬁed  in  several  patients  with  paragangliomas
13,14].  Finally,  several  head  and  neck  paragangliomas
ave  also  been  reported  in  patients  with  von  Hippel-Lindau
.
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Table  1  Main  phenotype-genotype  correlations  of  SDHx-
determined  paragangliomas.
SDHD  SDHC  SDHB
Head  and  neck  paraganglioma  +++  ++  ++
Multiple  paragangliomas  +++  +  ++
Thoracoabdominopelvic  paraganglioma  ++  +  +++
Phaeochromocytoma  +  ±  ++
Bilateral  phaeochromocytoma  +  —  +
Family history  of  paraganglioma ++  +  +
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d16  
isease,  but,  in  most  cases,  these  patients  also  presented
ther  typical  features  of  this  syndrome  (renal  cancer,  hae-
angioblastoma,  etc.)  [15].
The  SDHA, SDHB, SDHC  and  SDHD  genes  encode  for  the
our  proteins  of  mitochondrial  complex  II  or  succinate  dehy-
rogenase  (succinate  ubiquinone  oxidoreductase),  subunits
,  B,  C  and  D,  and  the  SDHAF2  gene  encodes  for  a  protein
hat  ensures  ﬂavination  of  succinate  dehydrogenase  subunit
,  required  for  the  activity  and  stabilization  of  the  com-
lex.  Succinate  dehydrogenase  is  located  at  the  junction
f  two  major  metabolic  pathways:  the  mitochondrial  respi-
atory  chain  and  the  Krebs  cycle.  It  catalyses  oxidation  of
uccinate  to  fumarate,  which  is  then  converted  to  malate
y  fumarase.  The  speciﬁc  trait  of  mitochondrial  complex
I,  compared  to  the  other  four  mitochondrial  complexes  of
he  respiratory  chain,  is  that  it  is  formed  by  four  proteins
ll  encoded  by  the  nuclear  genome.  Subunits  A  and  B  form
he  catalytic  core  of  the  enzyme,  while  subunits  C  and  D
nsure  anchorage  of  the  complex  in  the  internal  membrane
f  the  mitochondrion.  These  genes  behave  like  tumour  sup-
ressor  genes  i.e.  according  to  the  classical  model  proposed
y  Knudson,  a  heterozygous  germline  mutation  of  an  SDH
ene  is  always  associated  with  loss  of  the  normal  allele
f  the  gene  in  tumour  DNA.  Complete  and  selective  loss
f  succinate  dehydrogenase  enzymatic  activity  is  observed
n  the  tumour  regardless  of  the  type  of  SDH  gene  muta-
ion.  Paraganglioma  is  known  to  be  a  highly  vascular  tumour,
ut  this  peculiar  hypervascularization  has  now  been  more
learly  elucidated  and  can  be  explained  by  activation  of
ypoxia-inducible  factor  pathway  and  stimulation  of  angio-
enesis  (overexpression  of  EPAS, VEGF  genes  and  its  R1  and
2  receptors  in  the  tumour)  resulting  in  accumulation  of
uccinate,  secondary  to  inactivation  of  succinate  dehydro-
enase  in  tumour  cells.  Studies  in  various  in  vivo  and  in  vitro
xperimental  models  have  shown  that  succinate  accumu-
ation  induces  inhibition  of  prolyl  hydroxylase  activity  and
tabilization  of  the  hypoxia-inducible  factor  (HIF)  transcrip-
ion  factor,  leading  to  abnormal  stimulation  of  angiogenesis
n  the  presence  of  oxygen  [16]. This  role  of  angiogenesis
n  paraganglioma  tumourigenesis  has  opened  up  new  thera-
eutic  approaches,  such  as  the  use  of  new  anti-angiogenic
olecules,  which  will  be  evaluated  in  the  treatment  of
alignant  forms  of  the  disease.
SDHD  and  SDHB  nonsense  and  missense  mutations  and
ene  deletions  have  been  described  in  paraganglioma  and
haeochromocytoma  families,  but  also  in  apparently  spo-
adic  cases.  Mutations  of  the  SDHC  gene  have  been  reported
uch  more  rarely.  The  mutations  and  variants  identiﬁed  on
DHs  genes  all  over  the  world  are  collected  on  a  mutation
atabase  housed  by  the  Leyden  Open  Variation  Database
LOVD  database)  available  from  the  following  web  site:
ttp://chromium.liacs.nl/lovd.sdh/ [17]. Within  a  study
opulation  of  more  than  500  subjects  with  paragangliomas,
nly  two  families  with  head  and  neck  paragangliomas  (one
n  Holland  and  the  other  in  Spain)  were  identiﬁed  as  carrying
he  same  missense  mutation  of  the  SDHAF2  gene  [12].
The  national  PGL.NET  network  was  created  in  France  in
003  in  order  to  constitute  a  prospective  cohort  of  patients
anaged  for  paraganglioma  in  various  French  centres,  and
o  develop  specialized  genetic  testing  in  order  to  establish
enetic  counselling  (Fig.  1)  and  management  guidelines  for
hese  patients.  Many  multidisciplinary  teams  participated  in
a
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his  network  and  445  patients  were  recruited  over  a  5-year
eriod:  54%  of  these  445  patients  carried  an  SDHB, SDHC  or
DHD  mutation  [18]. About  10%  of  mutations  were  deletions
nvolving  one  or  several  exons.  These  large  deletions  are  not
etected  on  direct  sequencing  and  require  speciﬁc  quantita-
ive  techniques,  such  as  multiplex  ligation-dependent  probe
mpliﬁcation  (MLPA),  in  order  to  be  diagnosed.  An  early  age
t  diagnosis  (35  years),  a  family  history  of  paraganglioma
r  phaeochromocytoma,  multiple  paragangliomas  and  the
resence  of  metastases  were  identiﬁed  to  be  the  criteria
ost  commonly  associated  with  identiﬁcation  of  a  mutation
Table  1).  However,  16%  of  patients  presenting  an  apparently
poradic  paraganglioma  unexpectedly  carried  a  mutation.
t  has  therefore  now  been  established  that  genetic  testing
ust  be  performed  in  all  patients  with  paraganglioma.  In
perated  patients,  genetic  testing  could  be  guided  by  the
esults  of  immunohistochemical  analysis  of  SDHB  protein
xpression  performed  on  the  operative  specimen,  once  this
nalysis  can  be  performed  routinely  [14].
The  mean  age  at  diagnosis  in  the  PGL.NET  population  was
6.2  years  for  patients  with  a  mutation  versus  50.2  years
or  patients  without  mutation.  In  this  population,  hereditary
araganglioma  had  a  paediatric  onset  (a  paraganglioma  was
dentiﬁed  before  the  age  of  18  years  in  8.7%  of  subjects).
wo  SDHB  subjects  developed  a  paraganglioma  before  the
ge  of  10  years  (6  and  8  years)  and  nine  before  the  age  of
5  years  (11.7%).  The  youngest  SDHD  subject  was  10  years
ld  at  the  time  of  diagnosis  of  the  ﬁrst  paraganglioma  and
ve  (4.8%)  subjects  were  younger  than  15.  SDHD  subjects
ad  an  average  of  2.3  tumours  and  67%  had  more  than  two
umours  at  the  time  of  diagnosis.  A  head  and  neck  paragan-
lioma  was  present  in  almost  all  subjects  (97.7%)  and  12.3%
f  subjects  had  a thoracoabdominopelvic  paraganglioma.
DHB  subjects  had  a  paraganglioma  in  the  thorax,  abdomen
r  pelvis  in  56.2%  of  cases  and  in  the  head  and  the  neck  in
2.7%  of  cases.  In  line  with  the  literature,  only  a  small  num-
er  of  subjects  in  the  PGL.NET  population  were  identiﬁed
s  carrying  a  SDHC  mutation  (16  versus  130  for  SDHD  and  96
or  SDHB). They  had  a  similar  clinical  presentation  to  that
f  SDHD  subjects  with  predominantly  head  and  neck  para-
angliomas,  but  also  infradiaphragmatic  paragangliomas.
alidated  penetrance  databased  on  a  large  population  of
ubjects  with  a  homogeneous  supradiaphragmatic  and  infra-
iaphragmatic  phenotype  and  long-term  follow-up  are  not
vailable  at  the  present  time.  In  the  PGL.NET  population,
2%  of  subjects  under  the  age  of  40  with  an  SDHD  mutation
ad  a  cervical  paraganglioma  versus  21%  of  SDHB  subjects;
n  contrast,  at  the  age  of  60,  54.2%  of  SDHB  subjects  had  a
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Figure  1  Flow  diagram  for  genetic  testing  of  head  and  neck  paraganglioma.  The  gene  indicated  is  the  ﬁrst  gene  to  be  tested
(direct sequencing  then  MLPA).  In  the  absence  of  mutation  on  this  ﬁrst  gene,  the  other  SDHx  genes  must  be  tested.  If  the  clinical
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immunohistochemical  analysis  on  the  tumour  specimen  could  b
thoracoabdominopelvic  paraganglioma  versus  11.5%  of  SDHD
subjects  [18].
While  only  3.8%  of  SDHD  subjects  had  a  malignant  phe-
notype,  SDHB-determined  paragangliomas  were  malignant
(malignancy  deﬁned  by  the  presence  of  a  metastasis  in  an
extraparaganglionic  site)  in  37.5%  of  cases.  This  major  ﬁnd-
ing,  indicating  that  the  presence  of  a  SDHB  gene  mutation
is  a  prognostic  factor  for  malignancy  and  recurrence,  was
already  validated  by  a  previous  French  multicentre  study  on
314  subjects  followed  for  functional  thoracoabdominopelvic
paraganglioma  or  phaeochromocytoma  [19]. Identiﬁcation
of  a  SDHB  gene  mutation  is  also  a  factor  of  poor  prognosis,
as  multivariate  analysis  of  a  series  of  54  subjects  followed  in
France  for  paraganglioma  or  malignant  phaeochromocytoma
demonstrated  that  identiﬁcation  of  an  SDHB  mutation  was
the  only  risk  factor  for  mortality.  The  5-year  survival  prob-
ability  was  36%  for  subjects  with  an  SDHB  mutation  versus
67%  for  subjects  without  an  SDHB  mutation  with  a  calcu-
lated  median  survival  of  42  months  for  SDHB-mutant  patients
versus  244  months  for  wild-type  SDHB  patients  [20].
All  these  studies  were  used  to  determine  decisional  ﬂow
diagrams  for  the  organization  of  genetic  testing  [18,19].  The
ﬂow  diagram  presented  in  Fig.  1  indicates  the  ﬁrst  gene  to
be  tested  in  a  patient  with  head  and  neck  paraganglioma.  If
this  test  is  negative,  genetic  testing  should  be  continued  by
screening  for  other  susceptibility  genes.  Genetic  testing  of
hereditary  paraganglioma  also  now  allows  proposal  of  pre-
dictive  genetic  screening  for  all  ﬁrst-degree  relatives  of  the
index  case  carrying  a  mutation  on  one  of  the  susceptibility
genes,  and  proposal  of  clinical  tumour  screening  in  all  sub-
jects  identiﬁed  to  carry  the  mutation  previously  identiﬁed
in  the  index  case  [21]. Subjects  with  a  familial  mutation
on  the  SDHB  or  SDHC  genes  are  predisposed  to  develop
paragangliomas  and  require  clinical  screening.  Due  to  the
mechanism  of  maternal  genomic  imprinting  associated  with
SDHD  and  SDHAF2  genes,  the  gender  of  the  parent  transmit-
ting  the  mutation  must  be  taken  into  account  in  the  risk  of
developing  the  disease.  For  example,  subjects  who  received
the  mutation  from  their  mother  will  not  develop  the  disease,
but  could  transmit  the  mutation,  resulting  in  ‘‘skipped  gen-
erations’’  on  the  maternal  branch  of  these  families.  On  the
r
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ty,  multiple  paragangliomas)  and  the  genetic  test  is  negative,
sidered.
ther  hand,  subjects  who  received  an  SDHD  or  SDHAF2  gene
utation  from  their  father  are  at  high-risk  of  developing
he  disease  and  require  tumour  screening,  just  like  subjects
ith  an  SDHB  or  SDHC  mutation.  Hereditary  paraganglioma
s  a  disease,  which  can  start  in  childhood  (13%  of  subjects
f  the  PGL.NET  cohort  presented  signs  of  the  disease  before
he  age  of  20).  Presymptomatic  family  genetic  screening  in
inors  is  possible  from  the  age  of  6  years  in  accordance
ith  French  legislation  concerning  genetic  testing,  as  it  may
llow  diagnosis  of  small  tumours  in  subjects  with  a  positive
enetic  test  and,  more  importantly,  can  allow  the  prevention
f  metastatic  transformation  of  SDHB  tumours,  thereby  pro-
iding  a  real  direct  individual  medical  beneﬁt  to  the  tested
ubject.
onclusion
hese  discoveries  have  also  led  to  changes  in  the  man-
gement  of  these  patients.  It  has  now  been  established
hat  all  patients  with  a  hereditary  form  of  paragan-
lioma  require  genetic  counselling  and  management  by
 specialized  multidisciplinary  team  comprising  surgeons,
adiologists,  nuclear  medicine  physicians,  endocrinologists
nd  geneticists.  Patients  with  genetically  determined  head
nd  neck  paraganglioma  have  a  high-risk  of  developing  other
ead  and  neck  tumours,  as  well  as  tumours  in  the  thorax,
bdomen  and  pelvis.  These  tumours  may  be  associated  with
 catecholamine-secreting  phaeochromocytoma  responsible
or  paroxysmal  hypertension.  The  results  of  the  PGL.EVA  hos-
ital  clinical  research  programme  devoted  to  evaluation  of
creening  methods  to  detect  tumours  in  SDH-positive  carri-
rs,  in  which  more  than  240  patients  of  the  PGL.NET  network
ere  included  in  24  French  centres  and  underwent  stan-
ardized  laboratory  and  radiological  investigations  (total
etanephrine  assay,  chromogranin  A  assay,  MR  angiogra-
hy  of  the  head  and  neck,  CT  angiography  of  the  chest,
bdomen  and  pelvis, 123I-meta-iodobenzylguanidine  scintig-
aphy, 111In-pentetreotide  scintigraphy  or  Octreoscan®)
hould  lead  to  the  proposal  of  validated  guidelines  for  the
anagement  and  follow-up  of  these  patients  and  their  rela-
ives.
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